

TRADEMARK ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Diamics, Inc.		08/15/2007	CORPORATION: CALIFORNIA

RECEIVING PARTY DATA

Name:	General Electric Capital Corporation, as Agent
Street Address:	2 Bethesda Metro Center, Suite 600
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 4

Property Type	Number	Word Mark
Serial Number:	78799144	CER-COL
Serial Number:	78799137	C-MAP
Serial Number:	78748247	CYSRAY
Serial Number:	78748299	CYSAVE

CORRESPONDENCE DATA

Fax Number: (212)230-7735

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-318-6535

Email: traceybennett@paulhastings.com

Correspondent Name: Tracey D. Bennett

Address Line 1: c/o Paul Hastings, Janofsky & Walker LLP

Address Line 2: 75 E. 55th St.

Address Line 4: New York, NEW YORK 10022

ATTORNEY DOCKET NUMBER:	FIRST LIEN
NAME OF SUBMITTER:	Tracey D. Bennett

TRADEMARK

900085564

REEL: 003610 FRAME: 0443

\$115.00 78799144
OP

Signature:	/s/Tracey D. Bennett
Date:	08/28/2007

 Date: | 08/28/2007 |

Total Attachments: 60

source=Diamics Trademark Schedule#page1.tif
source=Diamics Trademark Schedule#page2.tif
source=Diamics Trademark Schedule#page3.tif
source=Diamics Trademark Schedule#page4.tif
source=Diamics Trademark Schedule#page5.tif
source=Diamics Trademark Schedule#page6.tif
source=Diamics Trademark Schedule#page7.tif
source=Diamics Trademark Schedule#page8.tif
source=Diamics Trademark Schedule#page9.tif
source=Diamics Trademark Schedule#page10.tif
source=Diamics Trademark Schedule#page11.tif
source=Diamics Trademark Schedule#page12.tif
source=Diamics Trademark Schedule#page13.tif
source=Diamics Trademark Schedule#page14.tif
source=Diamics Trademark Schedule#page15.tif
source=Diamics Trademark Schedule#page16.tif
source=Diamics Trademark Schedule#page17.tif
source=Diamics Trademark Schedule#page18.tif
source=Diamics Trademark Schedule#page19.tif
source=Diamics Trademark Schedule#page20.tif
source=Diamics Trademark Schedule#page21.tif
source=Diamics Trademark Schedule#page22.tif
source=Diamics Trademark Schedule#page23.tif
source=Diamics Trademark Schedule#page24.tif
source=Diamics Trademark Schedule#page25.tif
source=Diamics Trademark Schedule#page26.tif
source=Diamics Trademark Schedule#page27.tif
source=Diamics Trademark Schedule#page28.tif
source=Diamics Trademark Schedule#page29.tif
source=Diamics Trademark Schedule#page30.tif
source=Diamics Trademark Schedule#page31.tif
source=Diamics Trademark Schedule#page32.tif
source=Diamics Trademark Schedule#page33.tif
source=Diamics Trademark Schedule#page34.tif
source=Diamics Trademark Schedule#page35.tif
source=Diamics Trademark Schedule#page36.tif
source=Diamics Trademark Schedule#page37.tif
source=Diamics Trademark Schedule#page38.tif
source=Diamics Trademark Schedule#page39.tif
source=Diamics Trademark Schedule#page40.tif
source=Diamics Trademark Schedule#page41.tif
source=Diamics Trademark Schedule#page42.tif
source=Diamics Trademark Schedule#page43.tif
source=Diamics Trademark Schedule#page44.tif
source=Diamics Trademark Schedule#page45.tif
source=Diamics Trademark Schedule#page46.tif
source=Diamics Trademark Schedule#page47.tif
source=Diamics Trademark Schedule#page48.tif
source=Diamics Trademark Schedule#page49.tif

source=Diamics Trademark Schedule#page50.tif
source=Diamics Trademark Schedule#page51.tif
source=Diamics Trademark Schedule#page52.tif
source=Diamics Trademark Schedule#page53.tif
source=Diamics Trademark Schedule#page54.tif
source=Diamics Trademark Schedule#page55.tif
source=Diamics Trademark Schedule#page56.tif
source=Diamics Trademark Schedule#page57.tif
source=Diamics Trademark Schedule#page58.tif
source=Diamics Trademark Schedule#page59.tif
source=Diamics Trademark Schedule#page60.tif

FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 26, 2007, is made by each of the entities listed on the signature pages hereof (each a "Grantor" and, collectively, the "Grantors"), in favor of General Electric Capital Corporation ("GE Capital"), as administrative agent and collateral agent (in such capacity, together with its successors and permitted assigns, the "Administrative Agent") for the Lenders and the L/C Issuers (as defined in the Credit Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the First Lien Credit Agreement, dated as of June 26, 2007 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Borrower, Holdings, the Lenders and the L/C Issuers from time to time party thereto and Administrative Agent, the Lenders and the L/C Issuers have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has agreed, pursuant to a First Lien Guaranty and Security Agreement of dated as of June 26, 2007 herewith in favor of the Administrative Agent (the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Credit Agreement) of the other Loan Parties; and

WHEREAS, all of the Grantors are party to the Guaranty and Security Agreement pursuant to which the Grantors are required to execute and deliver this Intellectual Property Security Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders, the L/C Issuers and the Administrative Agent to enter into the Credit Agreement and to induce the Lenders and the L/C Issuers to make or continue to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Administrative Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations on the terms set forth in the Loan Documents, hereby mortgages, pledges and hypothecates to the Administrative Agent, for the benefit of the Secured Parties, and grants to the Administrative Agent, for the benefit of the Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor (the "Intellectual Property Collateral"):

(a) Copyrights.

(i) all of its Copyrights and registrations and applications for registration thereof and all registered IP Licenses and applications therefor providing for

the grant to such Grantor of any right under any Copyright, including, without limitation, those referred to on Schedule 1A hereto;

(ii) all renewals, reversions and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(b) Patents.

(i) all of its registered Patents and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1B hereto;

(ii) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(c) Trademarks.

(i) all of its Trademarks and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1C hereto;

(ii) all renewals and extensions of the foregoing;

(iii) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(iv) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Administrative Agent with respect to the security interest in the Intellectual Property Collateral

made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with such Grantor's Intellectual Property Collateral and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.


Section 6. Governing Law. This Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.


[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

IM US HOLDINGS, LLC
INVERNESS MEDICAL INNOVATIONS, INC.
ADVANTAGE DIAGNOSTICS CORPORATION
APPLIED BIOTECH, INC.
BINAX, INC.
FIRST CHECK DIAGNOSTICS CORP.
FOREFRONT DIAGNOSTICS, INC.
INCA ACQUISITION, INC.
INNOVATIVE MOBILITY, LLC
INSTANT TECHNOLOGIES, INC.
INVERNESS MEDICAL - BIOSTAR, INC.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II
INNOVATIONS RESEARCH, LLC
INVERNESS MEDICAL, LLC
ISCHEMIA TECHNOLOGIES, INC.
IVC INDUSTRIES, INC.
INNOVACON, INC.
OSTEX INTERNATIONAL, INC.
QUALITY ASSURED SERVICES, INC.
SELCARE TECHNOLOGY, INC.
SPDH, INC.
UNIPATH ONLINE, INC.
WAMPOLE LABORATORIES, LLC, as Grantors

Approved
As To Form

By: 
Name: David Teitel

 Legal Department


Title: President, Chief Financial Officer & Treasurer,
Vice President, Finance, Vice President, Vice
President, Finance, Vice President, Finance,
Vice President, Treasurer, Chief Financial
Officer, Vice President, Finance, Vice President,
Finance, President, President, Vice
President, Finance, Vice President, Finance,
Vice President, Finance, Vice President,
Finance, Vice President, Finance, Vice
President, Finance, Chief Financial Officer, Vice
President, Finance, President, Vice
President, Vice President

[SIGNATURE PAGE TO FIRST LIEN IP SECURITY AGREEMENT]

LEGAL_US_B # 75504384

ACCEPTED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 

Name:

Title:

Andrew D Moore
Duly Authorized Signatory

[SIGNATURE PAGE TO FIRST LIEN IP SECURITY AGREEMENT]

LEGAL_US_E # 75504384

TRADEMARK
REEL: 003610 FRAME: 0450

**SCHEDULE 1A
TO
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. COPYRIGHTS

None.

B. COPYRIGHT APPLICATIONS

None.

C. IP LICENSES

None.

**SCHEDULE 1B
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED PATENTS

[Include Owner, Registration Number and Date]

B. PATENT APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

[FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT]

**TRADEMARK
REEL: 003610 FRAME: 0452**

File Number	Country	Filing date	Filing number	Grant date	Grant number	List of Owners/Assignees	Expiry
IM0089	AT	19/MAR/2004	GMI9005/2004			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	AU	19/MAR/2004	2004254568			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	BR	19/MAR/2004	P10411059.5			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	CA	19/MAR/2004	2528108			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	CN	19/MAR/2004	20048015572.7			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	CZ	19/MAR/2004	2005-17219			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	DE	19/MAR/2004	21202400302.5	10/APR/2006	16422	Advantage Diagnostics Corporation	19/MAR/2014
IM0089	DK	19/MAR/2004	BA200500290	06/APR/2006	212004000032.5	Advantage Diagnostics Corporation	19/MAR/2024
IM0089	EP	19/MAR/2004	04785762.8	13/APR/2007	DK200500290	Advantage Diagnostics Corporation	19/MAR/2024
IM0089	HK	19/MAR/2004	08106552.1			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	JP	19/MAR/2004	2006-509248			Advantage Diagnostics Corporation	19/MAR/2019
IM0089	KR	19/MAR/2004	20-2005-7000007			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	MX	19/MAR/2004	PAJu/2005/000303			Advantage Diagnostics Corporation	18/MAR/2024
IM0089	PT	19/MAR/2004	2005003732			Advantage Diagnostics Corporation	19/MAR/2012
IM0089	RU	19/MAR/2004	2005138919	27/NOV/2006	58717	Advantage Diagnostics Corporation	19/MAR/2014
IM0089	UA	19/MAR/2004	200512159M	15/JAN/2007	19871	Advantage Diagnostics Corporation	08/JUN/2023
IM0089	US	06/JUN/2003	10456771	22/AUG/2000	6106732	Applied Biotech, Inc.	28/JUL/2022
AB10005	CA	23/JUL/2002	2465404	15/APR/2003	6548309	Applied Biotech, Inc.	27/OCT/2020
IM0079	US	02/JUN/2003	10453317	17/OCT/2006	2342141	Binax, Inc.	16/APR/2018
BNX0001	US	16/APR/1998	091060885	28/JAN/2004	98810035.8	Binax, Inc.	19/MAR/2018
BNX0002	US	19/MAR/1998	091044677	03/JAN/2007	1107773	Binax, Inc.	25/AUG/2019
BNX0003	AU	25/AUG/1998	56933399	30/JAN/2003	759833	Binax, Inc.	25/AUG/2019
BNX0003	CA	25/AUG/1998	2342141			Binax, Inc.	25/AUG/2019
BNX0003	CN	25/AUG/1998	99810035.8			Binax, Inc.	25/AUG/2019
BNX0003	EP	25/AUG/1998	99943941.7			Binax, Inc.	25/AUG/2019
BNX0003	JP	25/AUG/1998	2000-565804			Binax, Inc.	25/AUG/2019
BNX0003	MX	25/AUG/1998	PAJa/2001/002057	03/APR/2007	244714	Binax, Inc.	25/AUG/2018
BNX0003	US	25/AUG/1998	091139720			Binax, Inc.	20/SEP/2019
BNX0004	AT	20/SEP/1999	99948305.0	20/APR/2005	E289457	Binax, Inc.	20/SEP/2019
BNX0004	AU	20/SEP/1999	61513199	24/JUL/2003	759529	Binax, Inc.	20/SEP/2019
BNX0004	BE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	CA	20/SEP/1999	23427783			Binax, Inc.	20/SEP/2019
BNX0004	CH	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	CN	20/SEP/1999	99811042.6	17/AUG/2005	99811042.6	Binax, Inc.	20/SEP/2019
BNX0004	DE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	DK	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	EP	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	ES	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	FI	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	FR	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2018
BNX0004	GB	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	IE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	IT	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	JP	20/SEP/1999	2000-572764			Binax, Inc.	20/SEP/2019
BNX0004	MX	20/SEP/1999	PAJa/2001/002822			Binax, Inc.	20/SEP/2019
BNX0004	NL	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	PT	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019

BNX0004	SE	20/SEP/1999	9994830500	20/APR/2005	1113817	Binax, Inc.
BNX0004	US	16/SEP/1999	09397110	30/NOV/2004	6824987	Binax, Inc.
BNX0005	US	19/NOV/1999	094443211	27/APR/2004	6727573	Binax, Inc.
BNX0006	AU	11/DEC/2000	24293/01	16/MAR/2006	783777	Binax, Inc.
BNX0006	CA	11/DEC/2000	23936/28			Binax, Inc.
BNX0006	EP	11/DEC/2000	00989037.8			Binax, Inc.
BNX0006	US	10/DEC/1999	08458988	01/SEP/2005	2001241867	Binax, Inc.
BNX0006	AU	01/MAR/2001	2001241867			Binax, Inc.
BNX0007	CA	19/AUG/2002	2427693			Binax, Inc.
BNX0007	EP	01/MAR/2001	01913177.0			Binax, Inc.
BNX0007	JP	01/MAR/2001	2001-563134			Binax, Inc.
BNX0007	US	01/MAR/2000	6875181655			Binax, Inc.
BNX0008	US	15/JAN/2002	10/044920			Binax, Inc.
BNX0008	US	07/DEC/2005	11/295486			Binax, Inc.
BNX0009	US	27/FEB/2002	10/083475			Binax, Inc.
BNX0011	AU	24/FEB/2004	2004/2/16/189			Binax, Inc.
BNX0011	CA	24/FEB/2004	25/6/546			Binax, Inc.
BNX0011	CN	24/FEB/2004	2004/8/006045.4			Binax, Inc.
BNX0011	EP	24/FEB/2004	04714110.6			Binax, Inc.
BNX0011	HK	24/FEB/2004	06105386.0			Binax, Inc.
BNX0011	JP	24/FEB/2004	2006-503810			Binax, Inc.
BNX0011	US	24/APR/2004	10/784155			Binax, Inc.
BNX0012	CN	29/JUL/2005	2005/10/08/4739.5			Binax, Inc.
BNX0012	US	16/NOV/2004	10/989050			Binax, Inc.
BNX0012	US	23/MAY/2007	11/1740738			Binax, Inc.
BNX0015	US	08/DEC/2006	60/873865			Binax, Inc.
BNX0016	US	08/AUG/2006	60/836200			Binax, Inc.
BNX0018	CN	01/MAR/2005	2005/8/0013856.1			Binax, Inc.
BNX0018	EP	01/MAR/2005	05/724003.8			Binax, Inc.
BNX0019	AU	26/NOV/2003	2003/29551			Binax, Inc.
BNX0019	CA	26/NOV/2003	2541135			Binax, Inc.
BNX0019	CN	26/NOV/2003	2003/8/01/10715.2			Binax, Inc.
BNX0019	EP	26/NOV/2003	03787166.2			Binax, Inc.
BNX0019	IN	26/NOV/2003	17861/KC1/NP/2006			Binax, Inc.
BNX0019	JP	26/NOV/2003	2005-5/12/837			Binax, Inc.
BNX0019	NZ	26/NOV/2003	PCT/TJUS2003/037787			Binax, Inc.
BNX0019	US	16/NOV/2004	10/989873			Binax, Inc.
BNX0020	CN	17/FEB/2005	2005/8/009058.1			Binax, Inc.
BNX0020	EP	17/FEB/2005	05807858.5			Binax, Inc.
BNX0020	US	17/FEB/2005	11/06/2211			Binax, Inc.
BNX0020	US	17/FEB/2005	PT/TJS2005/005038			Binax, Inc.
BNX0021	CN	17/FEB/2005	2005/8/009058.1			Binax, Inc.
BNX0021	EP	17/FEB/2005	05723144.1			Binax, Inc.
BNX0021	IN	17/FEB/2005	PT/TJS2005/004896			Binax, Inc.
BNX0021	JP	17/FEB/2005	2006-554175			Binax, Inc.
BNX0021	US	17/FEB/2005	11/06/0113			Binax, Inc.
BNX0021	US	06/OCT/2005	PCT/US2005/035967			Binax, Inc.
BNX0022	CN	06/OCT/2005	PCT/US2005/035967			Binax, Inc.

BNX0022	EP	IN	JP	06/OCT/2005	PCT/US2005/035967	06/OCT/2025
BNX0022		BNX0022		06/OCT/2005	PCT/US2005/035967	06/OCT/2025
BNX0022		BNX0022		06/OCT/2005	11/244996	06/OCT/2024
BNX0022		US	US	08/DEC/2005	60873741	08/DEC/2007
BNX0026		US	US	05/JAN/2007	601678750	05/JAN/2008
BNX0027		US	US	20/OC/2006	601853264	20/OCT/2007
BNX0028		US	US	17/JAN/2007	601880791	17/JAN/2008
BNX0029		US	US	10/APR/2007	601910984	10/APR/2008
BNX0033		US	US	02/SEP/2003	101653321	02/SEP/2023
BNX0023		US	CA	22/MAY/2001	2409151	22/MAY/2021
AB10006		CA	AU	29/MAR/2002	2443077	29/MAR/2022
AB10007		AU	CN	07/DEC/2000	008176037	07/DEC/2020
BST0001		CN	DE	07/DEC/2000	019840711	07/DEC/2020
BST0001		DE	EP	07/DEC/2000	009840711	07/DEC/2020
BST0001		EP	FR	07/DEC/2000	009840711	07/DEC/2020
BST0001		FR	GB	07/DEC/2000	009840711	07/DEC/2020
BST0001		GB	JP	07/DEC/2000	2001-54519	07/DEC/2020
BST0001		JP	KR	07/DEC/2000	2002-7007547	07/MAR/2021
BST0001		KR	TW	07/MAR/2001	89126738	14/DEC/2019
BST0001		TW	US	14/DEC/2000	09/737635	14/DEC/2019
BST0001		US	US	09/JAN/2001	10/123750	09/JAN/2021
BST0001		US	TW	09/JAN/2001	89115794	10/JUL/2001
BST0002		TW	DE	20/MAR/1991	919100560	29/NOV/2006
BST0004		DE	EP	20/MAR/1991	919100560	008170037
BST0004		EP	ES	20/MAR/1991	919100560	008170037
BST0004		ES	FR	20/MAR/1991	919100560	008170037
BST0004		FR	GB	20/MAR/1991	919100560	008170037
BST0004		GB	HK	20/MAR/1991	971023087	008170037
BST0004		HK	IT	20/MAR/1991	971000560	008170037
BST0004		IT	JP	20/MAR/1991	919100560	008170037
BST0004		JP	DE	18/SEP/1990	909146151	008170037
BST0005		DE	EP	18/SEP/1990	909146151	008170037
BST0005		EP	FR	18/SEP/1990	909146151	008170037
BST0005		FR	GB	18/SEP/1990	909146151	008170037
BST0005		GB	HK	18/SEP/1990	909146151	008170037
BST0005		HK	IT	18/SEP/1990	971023167	008170037
BST0005		IT	JP	18/SEP/1990	909146151	008170037
BST0005		JP	JP	18/SEP/1990	2-513789	008170037
BST0005		JP	JP	18/SEP/1990	10-5911	008170037
BST0005		JP	US	31/JUL/1992	07923304	21/NOV/1995
BST0005		US	US	28/MAR/1995	08442600	17/JUN/1997
BST0005		US	DE	11/FEB/1992	929062990	26/FEB/1997
BST0005		DE	EP	11/FEB/1992	929062990	24/JUL/2002
BST0005		EP	ES	11/FEB/1992	929062990	24/JUL/2002
BST0005		ES	FR	11/FEB/1992	929062990	24/JUL/2002
BST0005		FR	GB	11/FEB/1992	929062990	24/JUL/2002
BST0005		GB	HK	11/FEB/1992	981006959	21/MAR/2003
BST0005		HK			981006959	1001889
						Inverness Medical - Biostar Inc.

BST0006	IT	JP	11/FEB/1992	92090299.0	24/JUL/2002	0524501	Inverness Medical - Biostar Inc.
BST0006	JP	11/FEB/1992	5057599/92	2001-31/2846	28/JUL/2006	3833507	Inverness Medical - Biostar Inc.
BST0006	JP	16/SEP/2003	2003-3-23-351		27/AUG/1996	5550063	Inverness Medical - Biostar Inc.
BST0006	US	10/JUN/1993	08/075347		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0006	DE	11/FEB/1992	920907304.7		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0007	EP	11/FEB/1992	920907304.7		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0007	ES	11/FEB/1992	920907304.7		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0007	FR	11/FEB/1992	920907304.7		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0007	GB	11/FEB/1992	920907304.7		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0007	HK	11/FEB/1992	98100899.5		24/MAR/2000	1001890	Inverness Medical - Biostar Inc.
BST0007	IT	11/FEB/1992	920907304.7		25/NOV/1988	6922/7655.6	Inverness Medical - Biostar Inc.
BST0008	BE	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	DE	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	EP	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	ES	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	FR	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	GB	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	HK	01/OCT/1991	91308968.6		10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
BST0008	JP	24/SEP/1992	1986039/98		08/SEP/2000	31077787	Inverness Medical - Biostar Inc.
BST0008	JP	24/SEP/1992	254562/92		02/OCT/1998	2834850	Inverness Medical - Biostar Inc.
BST0008	US	10/JUN/1993	08/076326		09/JAN/1996	5482830	Inverness Medical - Biostar Inc.
BST0009	US	17/APR/1995	08/1403565		21/SEP/1998	5855377	Inverness Medical - Biostar Inc.
BST0009	US	31/MAY/1995	08/1456040		13/MAY/1997	5829214	Inverness Medical - Biostar Inc.
BST0009	US	31/MAY/1995	08/455652		09/FEB/1998	5859272	Inverness Medical - Biostar Inc.
BST0009	US	10/JUN/1993	08/076719		23/MAY/1995	5418136	Inverness Medical - Biostar Inc.
BST0009	EP	10/JUN/1993	01108521.4		23/MAY/2007	1126278	Inverness Medical - Biostar Inc.
BST0009	EP	10/JUN/1993	938115341.7		14/DEC/2005	0727038	Inverness Medical - Biostar Inc.
BST0009	EP	10/JUN/1993	05027236.8		14/DEC/2005	0727038	Inverness Medical - Biostar Inc.
BST0009	EP	10/JUN/1993	939115341.7		23/MAY/2007	1126278	Inverness Medical - Biostar Inc.
BST0009	EP	10/JUN/1993	01108521.4		13/OCT/2006	1003304	Inverness Medical - Biostar Inc.
BST0011	EP	10/JUN/1993	98102355.0		10/JUN/2011	1236593	Inverness Medical - Biostar Inc.
BST0011	EP	10/JUN/1993	2001-236186		28/APR/2005	0727038	Inverness Medical - Biostar Inc.
BST0011	EP	10/JUN/1993	2001-236186		01/AUG/2003	3456984	Inverness Medical - Biostar Inc.
BST0011	JP	10/JUN/1993	2001-236411		26/DEC/2003	3506703	Inverness Medical - Biostar Inc.
BST0011	JP	10/JUN/1993	1984-505280		31/MAR/2006	3787143	Inverness Medical - Biostar Inc.
BST0011	JP	10/JUN/1993	276389/2004		23/APR/2004	3547723	Inverness Medical - Biostar Inc.
BST0011	JP	03/AUG/2001	2001-236198		26/DEC/2003	3507048	Inverness Medical - Biostar Inc.
BST0011	JP	03/AUG/2001	2001-236186		27/FEB/1995	5494829	Inverness Medical - Biostar Inc.
BST0011	US	10/JUN/1993	08/075128		20/MAY/1997	5631171	Inverness Medical - Biostar Inc.
BST0011	US	31/MAY/1995	08/1455493		20/MAR/2016	2020000	Inverness Medical - Biostar Inc.
BST0011	US	20/MAR/1995	08/619961		09/MAY/2000	6060237	Inverness Medical - Biostar Inc.
BST0011	US	17/JAN/1995	08/375151		12/MAR/2002	6355429	Inverness Medical - Biostar Inc.
BST0020	US	21/OCT/1999	091425072		31/AUG/2004	6783938	Inverness Medical - Biostar Inc.
BST0020	US	18/OCT/2001	09/982658		03/SEP/1996	5552272	Inverness Medical - Biostar Inc.
BST0021	US	10/JUN/1993	08/075348		30/JUL/1995	5541057	Inverness Medical - Biostar Inc.
BST0022	US	10/JUN/1993	08/075952		15/JUN/2005	69434406.0	Inverness Medical - Biostar Inc.
BST0023	DE	02/DEC/1994	94308983.9		02/DEC/2014		

BST0023	EP	02/DEC/1994	943088983.9	15/JUN/2005	0659437
BST0023	ES	02/DEC/1994	943088983.9	15/JUN/2005	0659437
BST0023	FR	02/DEC/1994	943088983.9	15/JUN/2005	0659437
BST0023	GB	02/DEC/1994	943088983.9	15/JUN/2005	0659437
BST0023	HK	02/DEC/1994	98100898.6	28/SEP/2005	1001885
BST0023	IT	02/DEC/1994	943088983.9	15/JUN/2005	0659437
BST0023	US	02/DEC/1993	08/162401	27/FEB/1996	5494801
BST0024	AU	21/JUN/1999	94603489	26/SEP/2002	747986
BST0024	CA	21/JUN/1999	2334554	03/MAY/2005	2345454
BST0024	CN	21/JUN/1999	93806819.5	07/APR/2004	98306819.5
BST0024	DE	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	EP	21/JUN/1999	93833568.0	12/NOV/2003	1089800
BST0024	ES	21/JUN/1999	93933568.0	12/NOV/2003	1089800
BST0024	FR	21/JUN/1999	93933568.0	12/NOV/2003	1089800
BST0024	GB	21/JUN/1999	93833568.0	12/NOV/2003	1089800
BST0024	HK	21/JUN/1999	01107099.4	30/SEP/2004	1036236
BST0024	IN	21/JUN/1999	IN/PC/T2000/000662	12/NOV/2003	1089800
BST0024	IT	21/JUN/1999	93933568.0	12/NOV/2003	1089800
BST0024	JP	21/JUN/1999	2004-297557	16/FEB/2007	3916889
BST0024	JP	21/JUN/1999	2000-556649	28/JAN/2006	121411A
BST0024	MY	22/JUN/1999	P19902560	30/JUN/2013	N-121230
BST0024	SG	21/JUN/1999	200007494.B	20/FEB/2011	6090572
BST0024	TW	24/JUN/1999	881105651	18/JUL/2000	6207445
BST0024	US	26/JUN/1998	09105309	27/MAR/2001	6207445
BST0024	US	17/JUL/2000	09167394	20/AUG/2004	772685
BST0025	AU	06/MAR/2000	37271/00		
BST0025	CA	06/MAR/2000	2366307		
BST0025	CN	06/MAR/2000	00805077.5		
BST0025	EP	06/MAR/2000	00916114.2		
BST0025	HK	06/MAR/2000	02104875.0	02/JUN/2006	199289
BST0025	IN	06/MAR/2000	IN/PC/T2001/000958		
BST0025	JP	06/MAR/2000	2000-605207		
BST0025	KR	06/MAR/2003	10-2001-7011848	19/JAN/2007	0374525
BST0025	SG	06/MAR/2000	200105414.7	28/NOV/2003	83390
BST0025	TW	06/APR/2000	89104986	11/DEC/2001	N-146426
BST0025	US	18/MAR/1999	09/272641	11/SEP/2001	6287783
BST0025	US	12/JUL/2001	091905146	03/AUG/2004	6770447
BST0026	CN	03/AUG/2000	00812202.4	23/JAN/2007	0675698
BST0026	EP	03/AUG/2000	09852567.6	11/JAN/2003	N-159901
BST0026	JP	03/AUG/2000	2001-515978	02/DEC/2003	6656428
BST0026	JP	03/AUG/2000	2005-37906	09/AUG/2001	732463
BST0026	KR	03/AUG/2000	10-2002-7004601		
BST0026	TW	26/SEP/2000	89115787		
BST0026	US	03/AUG/2000	091632343		
BST0027	AU	20/OCT/1987	4912997		
BST0027	EP	20/OCT/1987	97911650.2		
BST0027	HK	20/OCT/1987	W-990278.6		
BST0027	ID	20/OCT/1987	W-990278.6		
			22/DEC/2003	ID0012334	

BST0027	JP	20/OCT/1997	1998-520567	23/APR/2004	3547454
BST0027	JP	20/OCT/1997	2003-312436	12/JAN/2007	3900289
BST0027	TW	30/OCT/1997	86116219	21/AUN/2004	NI-203564
BST0027	US	15/OCT/1997	081950963	26/DEC/2006	7153651
BST0027	US	29/SEP/2000	091675518	23/AUG/2005	6933112
BST0027	US	17/DEC/1999	21941100	03/JUN/2004	770194
BST0028	AU	17/DEC/1999	200710135987.8		
BST0028	CN	17/DEC/1999	99815096.7		
BST0028	CN	17/DEC/1999	99815096.7		
BST0028	EP	17/DEC/1999	99963392.5		
BST0028	HK	17/DEC/1999	02100371.7		
BST0028	IN	17/DEC/1999	2811/DELNP/2006		
BST0028	JP	17/DEC/1999	2006-328456	28/JAN/2006	MY-1214114
BST0028	JP	21/DEC/1999	P19305641	29/AUG/2003	81760
BST0028	SG	17/DEC/1999	200103852.0	11/DEC/2001	NI-146232
BST0028	TW	17/DEC/1999	83122268		
BST0028	US	29/DEC/1998	09/223056	22/MAR/2006	00811055.7
BST0030	CN	03/AUG/2000	00811055.7		
BST0030	CN	03/AUG/2000	2005100340.5		
BST0030	EP	03/AUG/2000	00953653.9		
BST0030	IN	03/AUG/2000	IN/PC/T2002/00161		
BST0030	JP	03/AUG/2000	2004-219193		
BST0030	JP	03/AUG/2000	2001-51520	10/FEB/2005	3645523
BST0030	KR	04/AUG/2000	10-2002-7001557	19/NOV/2002	6483585
BST0030	US	04/AUG/2000	091633036		
BST0032	CN	14/APR/2004	20048010302.1		
BST0032	EP	14/APR/2004	04750150.7		
BST0032	HK	14/APR/2004	06102554.0		
BST0032	IN	14/APR/2004	3751/DELNP/2005		
BST0032	JP	14/APR/2004	2006-510051		
BST0032	KR	14/APR/2004	10-2005-7015594		
BST0032	US	16/APR/2003	10/4177833		
BST0032	ES	21/SEP/1999	146394	06/JUL/2000	146394
BST0032	JP	22/MAR/1999	11-025681	06/APR/2001	1110979
BST0032	US	22/MAR/1999	29/1024118	10/OCT/2000	D431867
BST0032	US	02/OCT/2003	10/680935		
ISC0009	US	02/OCT/2003	10/67963		
ISC0009	US	02/OCT/2003	10/67963		
ISC0009	US	02/OCT/1998	09/165928	08/OCT/2002	6461875
ISC0009	US	02/OCT/1998	09/165581	10/DEC/2002	6492178
ISC0009	US	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	AT	10/JUL/1992	10006197	26/AUG/1999	705400
ISC0009	AU	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	BE	10/JUL/1992	92915563.8	02/MAY/2001	P19206312.8
ISC0009	BR	10/JUL/1992	P19206312.8	10/JAN/2006	2113266
ISC0009	CA	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	CH	10/JUL/1992	92915563.8	09/MAR/2005	69233467.4
ISC0009	DE	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	DK	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	EP	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	EP	01/DEC/2003	03027486.4	10/JUL/2012	10/JUL/2012

ES	10/JUL/1992	92915563.8	09/MAR/2006	0596925	Ischemia Technologies, Inc.
FR	10/JUL/1992	92915563.8	09/MAR/2006	0596925	Ischemia Technologies, Inc.
GB	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
GR	10/JUL/1992	92915563.8	08/MAR/2005	0593499	Ischemia Technologies, Inc.
IE	24/JUL/1992	1992/2421	18/FEB/2006	84165	Ischemia Technologies, Inc.
IE	02/AUG/2005	2005/0515	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	IT	10/JUL/1992	92915563.8	01/JUN/2001	3194952
ISC0005	JP	10/JUL/1992	503561/93	23/OCT/1998	239947
ISC0005	KR	10/JUL/1992	700225/1994	09/MAR/2005	0596925
ISC0005	LU	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0005	MC	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0005	NL	10/JUL/1992	928115563.8	01/MAR/2005	0596925
ISC0005	NO	10/JUL/1992	1994/0256	16/DEC/2002	313900
ISC0005	PT	24/JUL/1992	100724	14/APR/1998	108724
ISC0005	SE	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0005	US	26/JUL/1991	07775683	13/JUL/1993	5227307
ISC0005	US	12/FEB/1993	08/016971	01/MAR/1994	5250519
ISC0006	EP	01/OCT/1999	99950055.6	05/NOV/2002	6475743
ISC0006	US	02/OCT/1998	09/165961	04/JUL/2006	7070937
ISC0006	US	29/MAR/2001	09/1820416	27/MAY/2004	769727
ISC0006	US	30/AUG/2002	10/232341		
ISC0006	US	31/JAN/2005	11/10/9020		
ISC0007	EP	30/MAY/2002	02/34574.3		
ISC0007	US	01/OCT/2002	10/147734		
ISC0010	AU	01/OCT/1999	64095199		
ISC0010	CA	01/OCT/1999	2344762		
ISC0010	EP	01/OCT/1999	999511710.5		
ISC0010	JP	01/OCT/1999	2000-574907		
ISC0010	US	15/APR/2003	10/1414469		
ISC0010	US	15/APR/2003	10/1413832		
ISC0010	US	15/APR/2003	10/1413835		
ISC0010	US	15/APR/2003	10/1413831		
ISC0011	US	13/DEC/2002	10/318263		
ISC0011	US	12/JAN/2005	11/033766		
ISC0012	AU	26/NOV/2002	2002352959		
ISC0012	CA	26/NOV/2002	2468236		
ISC0012	EP	26/NOV/2002	02789919.4		
ISC0012	JP	26/NOV/2002	2003-547926		
ISC0012	US	26/NOV/2002	10/304610		
ISC0012	US	01/MAY/2006	1/1415929		
ISC0013	AU	30/APR/2002	2002305335		
ISC0013	CA	30/APR/2002	2446187		
ISC0013	DE	30/APR/2002	02734148.6	27/DEC/2006	60217102.4
ISC0013	EP	30/APR/2002	02734148.6	27/DEC/2006	1392150
ISC0013	FR	30/APR/2002	02734148.6	27/DEC/2006	1392150
ISC0013	GB	30/APR/2002	02734148.6	27/DEC/2006	1392150
ISC0013	JP	30/APR/2002	2002-568901		
ISC0013	US	04/MAY/2001	09/649556		

ISC0014	AU	29/APR/2002	2002308530	Ischemia Technologies, Inc.
ISC0014	CA	29/APR/2002	2446329	Ischemia Technologies, Inc.
ISC0014	EP	29/APR/2002	02768865.6	Ischemia Technologies, Inc.
ISC0014	JP	29/APR/2002	2002-585988	Ischemia Technologies, Inc.
ISC0014	US	01/MAY/2001	09/846411	Ischemia Technologies, Inc.
ISC0015	AU	05/MAY/2004	2004240557	Ischemia Technologies, Inc.
ISC0015	CA	05/MAY/2004	2524530	Ischemia Technologies, Inc.
ISC0015	CN	05/MAY/2004	200480013619.0	Ischemia Technologies, Inc.
ISC0015	EP	05/MAY/2004	200480013679.4	Ischemia Technologies, Inc.
ISC0015	HK	05/MAY/2004	06/110013.6	Ischemia Technologies, Inc.
ISC0015	IL	05/MAY/2004	177781	Ischemia Technologies, Inc.
ISC0015	IN	05/MAY/2004	2131/IKOLNP/2005	Ischemia Technologies, Inc.
ISC0015	JP	05/MAY/2004	2006-532878	Ischemia Technologies, Inc.
ISC0015	KR	05/MAY/2004	2005-7029321	Ischemia Technologies, Inc.
ISC0015	NZ	05/MAY/2004	543538	Ischemia Technologies, Inc.
ISC0015	SG	05/MAY/2004	200507044.7	Ischemia Technologies, Inc.
ISC0015	US	19/MAY/2003	10/441155	Ischemia Technologies, Inc.
ISC0015	US	22/DEC/2005	11/317831	Ischemia Technologies, Inc.
ISC0016	EP	23/JAN/2006	06/719255.3	Selfcare
SELF D0001	US	10/MAR/1998	29/084813	Selfcare
SELF D0001	US	24/SEP/1998	094066	Selfcare
			20/APR/1998	D408292
			04/APR/2000	D422217

**SCHEDULE 1C
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED TRADEMARKS

[Include Owner, Registration Number and Date]

B. TRADEMARK APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

[FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT]

TRADEMARK
REEL: 003610 FRAME: 0464

B72312007

TRADEMARK
REEL: 003610 FRAME: 0466

Accessed JM - HK activity and negative 502 - US funds as of 6/23/2007

TRADEMARK
REEL: 003610 FRAME: 0469

**COUNTERPART TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of June 29, 2007, is delivered pursuant to that certain First Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedules IA, IB and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedules IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

BIOSITE INCORPORATED

By: 
Name: David Teitel
Title: Treasurer

Approved
As To Form


Legal Department

[SIGNATURE PAGE TO FIRST LIEN COUNTERPART TO IP SECURITY AGREEMENT]

LEGAL_US_E # 75434690

TRADEMARK
REEL: 003610 FRAME: 0471

SUPPLEMENTAL SCHEDULES
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Biosite Incorporated as a Grantor to the First Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of June 29, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Biosite Incorporated only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the *Agreement*.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of patents

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Polypeptides Related to Natriuretic Peptides and Methods of their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	2522709 04/19/2004	
Polypeptides Related to Natriuretic Peptides and Methods of Their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	10/827919 04/19/2004	
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/453234 12/01/1999	6794132 09/21/2004
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils Buechler, Joe Valkirs, Gunars E.	10/111365 04/01/2002	7135287 11/14/2006
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/521060 09/13/2006	
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/456090 12/06/1999	6680209 01/20/2004
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	10/149737 06/06/2002	7189515 03/13/2007
Human Antibodies as Detection Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/685068 03/12/2007	
Assays and Kits for Detecting Analytes In the Presence of Cross-Reacting Substances	Valkirs, Gunars E.	08/006341 01/19/1993	5914241 06/22/1999
Methods for Concentrating Ligands Using Magnetic Particles	Valkirs, Gunars E.	09/054918 04/03/1998	6348318 02/19/2002
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	08/832985 04/04/1997	6057098 05/02/2000
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/563055 05/01/2000	6986986 01/17/2006

Title	Inventor	Application No.	Patent No.	Issue Date
		Filing Date		
Polyclonal Libraries	Gray, Jeff Buechler, Joe Valkirs, Gunars E.	08/835159 04/04/1997	6555310	04/29/2003
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	08/832935	5965375	10/12/1999
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	09/363960	6503722	01/07/2003
Recombinant Library Screening Methods	Dower, William J. Cwirla, Steven E.	07/517659 05/01/1990	5427908	06/27/1995
Recombinant Library Screening Methods	Dower, William J. Cwirla, Steven E.	08/376326 01/20/1995	5580717	12/03/1996
RECOMBINANT LIBRARY SCREENING METHODS	Dower, William J. Cwirla, Steven E.	08/450754 05/25/1995		
DIAGNOSTIC ASSAY FOR DETECTION OF CRYPTOSPORIDIUM PARVUM	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/158180 09/21/1998		
Diagnostic Assays for Detection of Cryptosporidium Parvum	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/877933 06/07/2001	7052858	05/30/2006
Diagnostic Assays for Detection of Giardia Lamblia	Buechler, Joe Govindaraj, Shanthi Gray, Jeff Valkirs, Gunars E.	10/155163 05/23/2002	6908739	06/12/2005
Diagnostic Assays for Detection of Entamoeba Histolytica	Valkirs, Gunars E. Buechler, Joe Gray, Jeff	09/158347 09/21/1998	6207395	03/27/2001
Chimeric Polyclonal Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/410903 10/02/1999	6420113	07/16/2002
Chimeric Polyclonal Antibodies	Buechler, Joe	10/193960 07/12/2002		
Use of a Tag to Enrich Polypeptides Libraries	Buechler, Joe Valkirs, Gunars Gray, Jeff	11/015628 12/16/2004		
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	09/754947 01/04/2001	6828110	12/07/2004

Title	Inventor	Application No.	Patent No.
		Filing Date	Issue Date
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	10/890083 07/12/2004	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/339744 01/08/2003	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/447300 05/27/2003	
Compositions and Methods for Phage Display of Polypeptides	Gray, Jeff Valkirs, Gunars E.	11/198920 08/05/2005	
Latent Protein C Assays and Their Uses for Diagnosis and/or Prognosis in Systemic Inflammatory Response Syndromes	Valkirs, Gunars E. Buechler, Joe	11/614836 12/21/2006	
High Sensitivity Secretagogin Assays and Their Uses for Diagnosis and/or Prognosis	Buechler, Joe Nakamura, Kevin	11/654901 01/17/2007	

TITLE	INVENTORS	CNTRY	SERIAL NO./ FILING DATE	REG NO./ REG. DATE
Devices and Methods for Performing Receptor Binding Assays Using Magnetic Particles	John Michael Anderberg David M. Gregory	USA	60/834,073 07/28/2006	
Methods and Compositions For Monitoring And Risk Prediction in Cardiorenal Syndrome	Gunars Valkirs Paul H. McPherson	USA	60/859,137 11/14/2006	
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome	Gunars Valkirs Paul H. McPherson	USA	60/891,342 02/23/2007	
Method and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis	Gunars Valkirs Paul H. McPherson	USA	60/859,136 11/14/2006	

BIOSITE Case Listing

Country	Application Number	Application Date	Parent Number	Grant Date	Title
United States of America	11/512743	8/29/2006			USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
United States of America	11/684498	3/9/2007			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF DISEASES OF THE AORTA
United States of America	11/752135	5/22/2007			USE OF Natriuretic Peptides as Diagnostic and Prognostic Indicators in Vascular Diseases
United States of America	07/583738	10/10/1990	50391512	2/25/1992	Fibrinogen-specific monoclonal antibody
United States of America	07/364053	6/8/1989	51120834	6/9/1992	Fibrin-specific monoclonal antibody
United States of America	07/835800	21/4/1992	5223410	6/29/1993	Method for production of antibodies using an antigen-free animal
United States of America	07/295568	1/10/1989	5028535	7/21/1991	Threshold Ligand-Receptor Assay
United States of America	08/284035	8/11/1994	5679526	10/21/1997	Threshold Ligand-Receptor Assay
United States of America	08/871900	6/1/1997	5939272	8/17/1999	Non-Competitive Threshold Ligand-Receptor Assays
United States of America	08/458276	6/27/1995	5922615	7/13/1999	Device for Ligand Receptor Methods
United States of America	09/249321	2/11/1999	6297080	10/22/2001	Device for Ligand Receptor Methods
United States of America	07/463150	1/10/1990	5089391	2/18/1992	Threshold Ligand-Receptor Assay
United States of America	07/583046	9/14/1990	5143852	9/1/1992	Antibodies to Ligand Analogues and Their Utility in Ligand-Receptor Assays
United States of America	07/808515	12/16/1991	5233042	8/3/1993	Novel Cocaine Derivatives and Protein and Polypeptide Cocaine Derivative Conjugates and Labels
United States of America	07/8864110			5/9/1995	Novel Barbiturate Derivatives and Protein and Polypeptide Barbiturate Derivative Conjugates and Labels

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	07/864108	4/6/1992	54470997	11/28/1995	AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864106	4/6/1992	5237057	8/17/1993	NOVEL TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	08/032598	3/17/1993	5302703	4/12/1994	TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864093	4/6/1992	5302715	4/12/1994	NOVEL BENZODIAZEPINE AND PROTEIN AND POLYPEPTIDE BENZODIAZEPINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864104	4/6/1992	5331109	7/19/1994	PHENCYCLIDINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PHENCYCLIDINE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/241061	5/11/1994	6777190	8/17/2004	CROSSTALK INHIBITORS AND THEIR USES
United States of America	08/101677	8/3/1993	5525524	6/11/1996	CROSSTALK INHIBITORS AND THEIR USES
United States of America	07/887526	5/21/1992	5458852	10/17/1995	DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF A REAGENT WITHOUT MEMBRANES
United States of America	08/447895	5/23/1995	6019944	2/1/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/447981	5/23/1995	5885527	3/23/1999	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/828041	3/27/1997	6156270	12/5/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/902775	7/30/1997	62271040	8/7/2001	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/105669	3/3/1997	6143576	11/7/2000	NON-POROUS DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS
United States of America	09/613650	7/11/2000			DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/805653	3/13/2001	6767510	7/27/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/982629	10/18/2001	6905882	6/14/2005	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/697351	10/29/2003			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/792258	3/2/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	11/022297	12/22/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/416034	4/3/1995	5710256	1/20/1998	METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/973997	11/9/1992	6037456	3/14/2000	PROPOXYPHENE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PROPOXYPHENE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/071203	6/1/1993	5480792	1/2/1996	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/458901	6/2/1995	5985579	11/16/1999	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/101782	8/3/1993	58851776	12/22/1998	CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS
United States of America	08/311098	9/23/1994	5763189	6/9/1998	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN MICROPARTICLES USING NOVEL COMPOUNDS
United States of America	08/409298	3/23/1995	6251687	6/26/2001	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS
United States of America	08/389969	2/15/1995	5610283	3/11/1997	OPIATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE OPIATE DERIVATIVE CONJUGATION AND LABELS
United States of America	08/423582	4/18/1995	5795725	8/18/1998	NOVEL METHODS FOR THE ASSAY OF TROponin I AND T AND COMPLEXES OF TROponin I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	08/6333248	4/18/1996	6174686	1/16/2001	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	08/7769077	12/18/1996	6627404	9/30/2003	METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	09/349194	7/7/1999	6939678	9/6/2005	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/425318	10/21/1999	65779687	6/17/2003	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/6887051	10/12/2000	6991907	1/31/2006	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	10/459006	6/10/2003			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	10/850954	5/21/2004			NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	11/673397	2/9/2007			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	08/517949	8/22/1995	6803040	10/12/2004	DERIVATIVES OF TRICYCLIC ANTIDEPRESSANTS AND PROTEIN AND POLYPEPTIDE TRICYCLIC ANTIDEPRESSANT DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08704804	8/26/1996	6391265	5/21/2002	DEVICES INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	10/153423	5/21/2002			DEVICES FOR INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	08/620597	3/22/1996	5824799	10/20/1998	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	09776599	2/11/2001	7033984	8/17/2006	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/274534	7/12/1994	6238931	5/29/2001	FLUORESCENCE ENERGY TRANSFER AND PARTICLES
United States of America	09/066255	4/24/1998	6984844	11/15/2005	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	11/448613	6/6/2006			HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08749702	11/15/1996	6113855	9/5/2000	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	09/612815	7/10/2000	6669807	12/30/2003	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	10/746282	12/24/2003			DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	08/837309	4/9/1997	6544797	4/8/2003	COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	10/338182	1/7/2003			NOVEL COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	09/081722	5/13/1998	6670196	12/30/2003	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	10/697356	10/29/2003	7202042	4/10/2007	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	08/821888	3/21/1997	5947124	9/7/1999	DIAGNOSTIC FOR DETERMINING THE TIME OF A HEART ATTACK
United States of America	08/942370	10/21/1997	6106779	8/22/2000	LYSIS CHAMBER FOR USE IN AN ASSAY DEVICE
United States of America	09/003066	1/5/1998	6074616	6/13/2000	MEDIA CARRIER FOR AN ASSAY DEVICE

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	09/545699	4/6/2000	6332894	5/21/2002	MEDIA CARRIER FOR AN ASSAY DEVICE
United States of America	07/299277	1/23/1989	5202234	4/13/1993	MYOCARDIAL INFARCTION ASSAY
United States of America	07/882299	5/13/1992	5328692	7/5/1994	FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT
United States of America	09/358130	7/20/1999	63073919	10/16/2001	REVERSE-FLOW CENTRIFUGAL FILTRATION METHOD
United States of America	11/204764	8/15/2005			USE OF A GLUTATHIONE PEROXIDASE 1 AS A MARKER IN CARDIOVASCULAR CONDITIONS
United States of America	09/003090	1/5/1998	6830731	12/14/2004	IMMUNOASSAY FLUOROMETER
United States of America	10/267232	10/8/2002			IMMUNOASSAY FLUOROMETER
United States of America	10/841274	5/7/2004			IMMUNOASSAY FLUOROMETER
United States of America	09/003065	1/5/1998	6194222	2/27/2001	METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOAASSAYS
United States of America	09/712615	1/1/13/2000			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOAASSAYS
United States of America	11/676032	2/16/2007			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOAASSAYS
United States of America	08/933750	12/19/1997	6156521	12/5/2000	METHODS FOR THE RECOVERY AND MEASUREMENT OF TROPONIN COMPLEXES
United States of America	09/835298	4/13/2001			USE OF B-TYPE Natriuretic Peptide AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/389720	3/13/2003			USE OF B-TYPE Natriuretic Peptide AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/225082	8/20/2002			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/371149	2/20/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/673077	9/26/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/714078	11/14/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHODS OF USE THEREOF
United States of America	10/875800	6/23/2004			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/330696	12/27/2002			MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/728067	12/3/2003			USE OF THROMBUS PRECURSOR PROTEIN AND MONOCYTE CHEMOATTRACTANT PROTEIN AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	10/952275	9/27/2004			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS
United States of America	11/022552	12/23/2004			METHODS AND COMPOSITIONS FOR DETERMINING TREATMENT REGIMENS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	10/759216	1/20/2004			BIOMARKERS FOR SEPSIS
United States of America	11/543312	10/3/2006			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/690767	3/23/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/770608	6/28/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America					ARGININE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	10/139086	5/4/2002			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	11/205571	8/17/2005			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	10/331127	12/27/2002			METHOD AND SYSTEM FOR DISEASE DETECTION USING MARKER COMBINATIONS
United States of America	10/410572	4/8/2003			SYSTEM AND METHOD FOR IDENTIFYING A PANEL OF INDICATORS
United States of America	10/603891	6/24/2003			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	11/737621	4/19/2007			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/419059	4/17/2003			POLYPEPTIDES RELATED TO Natriuretic Peptides AND METHODS OF THEIR IDENTIFICATION AND USE OF USE THEREOF
United States of America	10/645874	8/20/2003			METHODS AND COMPOSITIONS FOR MEASURING BIOLOGICALLY ACTIVE Natriuretic Peptides AND FOR IMPROVING THEIR THERAPEUTIC POTENTIAL
United States of America	10/938760	9/9/2004			METHODS AND COMPOSITIONS FOR MEASURING Natriuretic Peptides AND USES THEREOF
United States of America	11/560425	11/16/2006			COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE Natriuretic Peptide ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION
United States of America	11/222494	9/7/2005			METHODS AND COMPOSITIONS FOR MEASURING CANINE BNP AND USES THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10778919	2/12/2004	6887952	5/3/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/080211	3/14/2005	6967107	11/22/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/184746	7/19/2005			N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/450150	6/9/2006			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLIC DISEASE

**SCHEDULE 1C
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks

COUNTRY	TRADEMARK	CLASS(ES)	APPL. NO	REG. NO.
			FILING DATE	ISSUE DATE
US	AN UNFAIR ADVANTAGE	1, 42	75609619 12/21/1998	2453707 05/22/2001
US	BIOSITE DISCOVERY AN UNFAIR ADVANTAGE & Design	1, 5, 42	75655110 03/05/1999	2456030 05/29/2001
US	OMNICLONAL	1, 5	75609841 12/21/1998	2476239 08/07/2001

MARK	COUNTRY	SERIAL NO. FILING DATE	REG. NO./ REG. DATE
MULTI MARKER INDEX	USA	78574,678 02/24/2005	

TRADEMARK
REEL: 003610 FRAME: 0491

Biosite (U.S. only)

Docket Number	Country	Mark	Mark Status	Portfolio Status	Owner No.	Application Date	Registration Date	Registration Number
071949-4501	United States of America	IN TIME TO DECIDE		Registered	Biosite Inc	78/056518	4/3/2001	7/30/2002 2601205
071949-4601	United States of America	NEW DIMENSIONS IN DIAGNOSIS		Registered	Biosite Inc	78/072981	7/9/2001	8/26/2003 2757467
071949-4701	United States of America	ASCEND MULTIMUNOASSAY		Registered	Biosite Inc	74/489582	2/14/1994	10/3/1995 1923243
071949-4801	United States of America	BIOSITE (Stylized)		Registered	Biosite Inc	74/260208	3/30/1992	9/28/1993 1794618
071949-4802	United States of America	BIOSITE (Stylized)		Registered	Biosite Inc	74/260475	3/30/1992	10/5/1993 1796567
071949-4819	United States of America	BIOSITE and Design		Registered	Biosite Inc	76/634473	3/28/2005	10/10/2006 3152581
071949-5101	United States of America	TRIAGE		Registered	Biosite Inc	74/525008	5/16/1994	2/6/1996 1954150
071949-5202	United States of America	TnP Stylized		Registered	Biosite Inc	75/172105	9/26/1996	1/14/2003 2673476
071949-6401	United States of America	EXPRESS TEST		Registered	Biosite Inc	75/075619	3/20/1996	12/1/1998 2207727
071949-6402	United States of America	EXPRESS TEST and Design		Registered	Biosite Inc	75/099733	5/2/1996	9/21/1998 2279640
071949-8101	United States of America	CARDIO PROFILER		Registered	Biosite Inc	78/178159	10/24/2002	6/7/2005 2960760

SUPPLEMENTAL SCHEDULES
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

The following Supplemental Schedules (the “*Schedules*”) of the Grantors with respect to that certain First Lien Intellectual Property Security Agreement among the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the “*Agreement*”) are being delivered pursuant to Section 7 of Schedule 7.15 to the First Lien Credit Agreement by and among the Borrower, Holdings, the Lenders and L/C Issuers party thereto, General Electric Capital Corporation, as Administrative Agent, Citizens Bank of Massachusetts, Fifth Third Bank and Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc., as Co-Documentation Agents and UBS Securities LLC, as Joint Lead Arranger and Syndication Agent dated as of June 26, 2007 (the “*Agreement*”). Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement. The Schedules give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Quality Assured Services, Inc., only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - None

SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks - Quality Assured Services, Inc.

Name of Mark	Serial Number	Status
Cafe PTINR	78857466	Approved 04-10-2007
QAS	78857429	Pending Approval (Published for opposition)
INRCare	78810066	Pending Approval (Published for opposition)
Town Hall Meeting	78867671	Pending Approval (Published for opposition)
The Best Way to Test	77030923	Pending Approval
IN-Range	78866759	Abandoned
Vitamin K Registry	78866731	Abandoned
PTINR.COM	78857424	Allowed for Registration on Supplemental Register
Vitamin K Food Diary	78866740	Allowed for Registration on Supplemental Register

**COUNTERPART TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of August 15, 2007, is delivered pursuant to that certain First Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

DIAMICS, INC.

By:

Name: Peter Gombrich

Title: Chairman and CEO

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT – DIAMICS, INC. – FIRST LIEN]
LEGAL_US_E # 75952773

TRADEMARK
REEL: 003610 FRAME: 0498

SUPPLEMENTAL SCHEDULES
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Diamics, Inc. as a Grantor to the First Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of August 15, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of certain of the capital stock of Diamics, Inc. only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.


**SCHEDULE 1A
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of patents

CERVICAL ANALYSIS SYSTEM AND COLLECTOR PATENTS



CERVICAL ANALYSIS SYSTEM AND COLLECTOR PATENTS

New claim added to U.S. system application

A system comprising:
means for collecting and maintaining the spatial orientation
of cervical cell clusters;
means for transferring a sample of the collected cell
clusters onto a slide while maintaining the spatial orientation of
the transferred sample and without changing or destroying the
morphological aspects of the transferred sample; and
a container with preservative for receiving the remaining
collected cervical cell clusters, the preservative maintaining the
morphological aspects of the remaining cell clusters and
their antigenicity.

ASSAY FOR INDICATING A CELL TISSUE CONDITION PATENT

Provisional application
60/885146
Filed Jan. 16, 2007

POINT OF CARE CERVICAL SCREENING SYSTEM

Provisional application
60/939533
Filed May 22, 2007

**SCHEDULE 1C
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks

TRADEMARKS

CYSAVE
SN 78/748299
Filed 11/7/05
Stat: Allowed

CYSRAY
SN 78/748247
Filed 11/7/05
Stat: Allowed

C-MAP
SN 78/799137
Filed 1/25/06
Stat: Allowed

CER-COL
SN 78/799144
Filed 1/25/06
Stat: Allowed

TRADEMARK
REEL: 003610 FRAME: 0505

RECORDED: 08/28/2007